Zhaohua Zhong

Zhaohua Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhaohua Zhong has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Capsid Protein VP1 of Coxsackievirus B Induces Cell Cycle Arrest by Up-Regulating Heat Shock Protein 70

    by Yao Wang, Shuoxuan Zhao, Yang Chen, Tianying Wang, Chaorun Dong, Xiaoman Wo, Jian Zhang, Yanyan Dong, Weizhen Xu, Xiaofeng Feng, et al.

    Manipulating cell cycle is one of the common strategies used by viruses to generate favorable cellular environment to facilitate viral replication. Coxsackievirus B (CVB) is one of the major viral pathogens of human myocarditis and cardiomyopathy. Because of its small genome, CVB depends on cellular machineries for productive replication. However, how the structural and non-structural components of CVB would manipulate cell cycle is not clearly understood. In this study, we demonstrated that the capsid protein VP1 of CVB type 3 (CVB3) induced cell cycle arrest at G1 phase. G1 arrest was the result of the decrease level of cyclin E and the accumulation of p27Kip1. Study on the gene expression profile of the cells expressing VP1 showed that the expression of both heat shock protein 70-1 (Hsp70-1) and Hsp70-2 was significantly up-regulated. Knockdown of Hsp70 resulted in the increased level of cyclin E and the reduction of p27Kip1. We further demonstrated that the phosphorylation of the heat shock factor 1, which directly promotes the expression of Hsp70, was also increased in the cell expressing VP1. Moreover, we show that CVB3 infection also induced G1 arrest, likely due to dysregulating Hsp70, cyclin E, and p27, while knockdown of Hsp70 dramatically inhibited viral replication. Cell cycle arrest at G1 phase facilitated CVB3 infection, since viral replication in the cells synchronized at G1 phase dramatically increased. Taken together, this study demonstrates that the VP1 of CVB3 induces cell cycle arrest at G1 phase through up-regulating Hsp70. Our findings suggest that the capsid protein VP1 of CVB is capable of manipulating cellular activities during viral infection.


  • Open Access

    Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer

    by Meng Zhou, Yanying Sun, Yifan Sun, Wanying Xu, Zhaoyue Zhang, Hengqiang Zhao, Zhaohua Zhong, Jie Sun

    Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer


  • Coxsackievirus B3 induces autophagic response in cardiac myocytes in vivo

    by Xia Zhai, Bing Bai, Bohai Yu, Tanying Wang, Huapeng Wang, Yao Wang, Huiyan Li, Lei Tong, Yan Wang, Fengmin Zhang, et al.

    Viral myocarditis is a common disease that contributes to dilated cardiomyopathy or heart failure. Coxsackievirus B (CVB) is one of the major causative pathogens of viral myocarditis. Previous studies have shown that autophagy is exploited to promote CVB replication in cell lines. To study whether cardiac myocytes respond to CVB infection in a similar way, viral myocarditis was established by the inoculation of 3-week-old BALB/c mice with CVB3. Electron microscopic observation showed that autophagosome-like vesicles were induced in the cardiac myocytes of mice infected by CVB3 at 3, 5, and 7 days after viral infection. The lipidated microtubule-associated protein 1 light chain 3 (LC3), LC3-II, was also significantly increased in both myocardium and the cardiac myocytes extracted from the ventricles of mice infected with CVB3. The increased LC3-II coincided with high level of viral RNA and proteins in both myocardium and isolated cardiac myocytes. Moreover, viral protein synthesis was significantly decreased in primary cardiac myocytes by the treatment with 3-methyladenine, an inhibitor of autophagy. The expression and the phosphorylation of extracellular signal regulated kinase (ERK) were also increased in both myocardium and in the isolated cardiac myocytes of the virus-infected mice, while the interplay of ERK with autophagic response remains to be studied. This study demonstrated that cardiac myocytes respond to CVB3 infection by increased formation of autophagosomes in vivo, which might be exploited for viral replication.


  • miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells

    by Xia Wu, Shuaiqin Wu, Lei Tong, Tian Luan, Lexun Lin, Shulan Lu, Wenran Zhao, Qianqian Ma, Huimin Liu, Zhaohua Zhong

    • 1 July 2003
      • Vol. 19  (4) , 349-50

    [Expressions of TNF-alpha and IL-1beta in human ischemic brain tissues].

    by Zhao-Hua Zhong, Guo-Zhong Li, Hu-Lun Li, Wen-Ran Zhao, Ye Tian, Dian-Jun Li, Hong-Xi Gu, Hai-Tao Wang, Xiu-Qin Dong

    To detect the expression of TNF-alpha and IL-1beta in human cerebral ischemic tissues. 13 cerebral specimens from patients died of cerebral infarction were divided into three groups, 5d, according to the lasting time of infarctions. The expression of TNF-alpha and IL-1beta in the cerebral ischemic tissues were examined by immnohistochemical staining. The contralateral tissues were employed as controls. The expression of TNF-alpha and IL-1beta in the cerebral ischemic tissues were significant higher than those in the contralateral tissues. The focal distribution of the TNF-alpha(+) and IL-1beta(+) cells was identical with the ischemic area. The expression of IL-1beta and TNF-alpha peaked at the 3rd to 5th and 2nd day after ichemia, respectively. There were no significant difference between the ischemic and contralateral brains at the 5th day after ischemia for the expression of TNF-alpha and IL-1beta. Our results showed the expression of TNF-alpha and IL-1beta in human strok of infarction were similar to those in animal experiments. It is suggested that TNF-alpha and IL-1beta are involved in cerebral ischemic injury, which will be helpful for developing clinically a novel therapy aiming at cerebral ischemic injury.